PL370913A1 - Środki farmaceutyczne zawierajace 5,7,14-triazatetracyklo [10.3.1.0(2,11).0(4,9)] heksadeka-2(11) 3,5,7,9-pentaen - Google Patents

Środki farmaceutyczne zawierajace 5,7,14-triazatetracyklo [10.3.1.0(2,11).0(4,9)] heksadeka-2(11) 3,5,7,9-pentaen

Info

Publication number: PL370913A1
Authority: PL; Poland
Prior art keywords: hexadeka; triazatetracyclo; pentaene; pharmaceuticals containing; pharmaceuticals
Prior art date: 2001-11-30

Application number

PL02370913A

Other languages

English (en)

Other versions

PL208080B1 (pl

Inventor

Ende Mary Tanya Am

Michael Christopher Roy

Scott Wendell Smith

Kenneth Craig Waterman

Sara Kristen Moses

Ernest Shing Quan

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2002-11-04

Publication date

2005-05-30

2002-11-04 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-05-30 Publication of PL370913A1 publication Critical patent/PL370913A1/pl

2011-03-31 Publication of PL208080B1 publication Critical patent/PL208080B1/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Psychology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Rheumatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL370913A 2001-11-30 2002-11-04 Postacie dawkowane zawierające 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹]heksadeka-2(11),3,5,7,9-pentaen i zastosowanie 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹] heksadeka-2(11),3,5,7,9-pentaenu PL208080B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33465201P	2001-11-30	2001-11-30

Publications (2)

Publication Number	Publication Date
PL370913A1 true PL370913A1 (pl)	2005-05-30
PL208080B1 PL208080B1 (pl)	2011-03-31

Family

ID=23308160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL370913A PL208080B1 (pl)	2001-11-30	2002-11-04	Postacie dawkowane zawierające 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹]heksadeka-2(11),3,5,7,9-pentaen i zastosowanie 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹] heksadeka-2(11),3,5,7,9-pentaenu

Country Status (31)

Country	Link
US (1)	US7771748B2 (pl)
EP (1)	EP1448235B1 (pl)
JP (2)	JP2005528330A (pl)
KR (2)	KR100892517B1 (pl)
CN (2)	CN1596128A (pl)
AR (1)	AR037592A1 (pl)
AT (1)	ATE356625T1 (pl)
AU (1)	AU2002351008B2 (pl)
BR (1)	BR0214806A (pl)
CA (1)	CA2467490C (pl)
DE (1)	DE60218885T2 (pl)
DK (1)	DK1448235T3 (pl)
ES (1)	ES2282492T3 (pl)
GT (1)	GT200200247A (pl)
IL (1)	IL161857A0 (pl)
MX (1)	MXPA04003807A (pl)
MY (1)	MY130619A (pl)
NO (1)	NO20042739L (pl)
NZ (1)	NZ532435A (pl)
PA (1)	PA8559501A1 (pl)
PE (1)	PE20040121A1 (pl)
PL (1)	PL208080B1 (pl)
PT (1)	PT1448235E (pl)
PY (1)	PY0228832A (pl)
RU (2)	RU2272629C2 (pl)
SI (1)	SI1448235T1 (pl)
SV (1)	SV2004001418A (pl)
TW (1)	TWI327471B (pl)
UY (1)	UY27553A1 (pl)
WO (1)	WO2003045437A1 (pl)
ZA (1)	ZA200403068B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
SE521512C2 (sv) *	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
WO2003045437A1 (en)	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
PT1578422E (pt) *	2002-12-20	2007-06-14	Niconovum Ab	Material particulado contendo nicotina fisicamente e quimicamente estável
WO2004103372A1 (en) *	2003-05-20	2004-12-02	Pfizer Products Inc.	Pharmaceutical compositions of varenicline
US7051606B2 (en) *	2004-01-30	2006-05-30	Andrx Labs Llc	Dosage form holder device and methods for immersion testing
MX2007004495A (es) *	2004-10-15	2007-05-10	Pfizer Prod Inc	Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
WO2006072832A1 (en) *	2005-01-07	2006-07-13	Pfizer Products Inc.	Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
EP1942875B1 (en) *	2005-08-24	2015-08-12	Rubicon Research Private Limited	Controlled release formulation
AU2007224584A1 (en)	2006-03-16	2007-09-20	Niconovum Ab	Improved snuff composition
CN101420939A (zh) *	2006-04-24	2009-04-29	辉瑞产品公司	用于药物递送装置的不对称膜
US20090130206A1 (en) *	2006-05-09	2009-05-21	Umesh Nandkumar Khatavkar	Controlled Release Compositions of an Antidepressant Agent
US20080145423A1 (en) *	2006-12-14	2008-06-19	Ajmal Ali Khan	Chewable tablet and method of formulating
WO2009027786A2 (en) *	2007-08-29	2009-03-05	Pfizer Inc.	Matrix dosage forms of varenicline
WO2009034431A2 (en)	2007-09-10	2009-03-19	Pfizer Inc.	Controlled-release dosage forms for varenicline
WO2009123580A1 (en) *	2008-04-01	2009-10-08	Schering-Plough Healthcare Products, Inc.	Chewable tablet and method of formulating
US8039620B2 (en)	2008-05-22	2011-10-18	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2432437A4 (en) *	2009-05-21	2012-12-19	Bionex Pharmaceuticals Llc	TWO- AND ONE-LAYER DOSAGE FORMS
EP2438054A1 (en)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
JP6272695B2 (ja)	2010-09-01	2018-01-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
CN102183182A (zh) *	2011-03-27	2011-09-14	雷鸣	一种烟花纸筒整形方法
WO2013163917A1 (zh)	2012-04-13	2013-11-07	连云港金康和信药业有限公司	化合物jk12a及其制备
KR20140087846A (ko) *	2012-12-31	2014-07-09	주식회사 삼양바이오팜	테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
KR20170038039A (ko) *	2014-07-30	2017-04-05	메르크 파텐트 게엠베하	분상, 직접 압축성 유형의 폴리비닐 알코올
JP2019501207A (ja) *	2016-01-08	2019-01-17	シーティーシーバイオ，インコーポレイテッド	バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤
KR102463733B1 (ko)	2017-06-30	2022-11-04	한미약품 주식회사	함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
EP3697392B1 (en)	2017-10-17	2023-11-15	Synthon B.V.	Tablets comprising tamsulosin and solifenacin
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko)	2018-09-21	2020-03-31	한미약품 주식회사	제어 방출용 바레니클린 제제
EP4125847A4 (en) *	2020-04-03	2024-06-19	Lpoxy Therapeutics, Inc.	ENTERAL AEROBIZATION THERAPY
JP2024536134A (ja)	2021-09-29	2024-10-04	ループオキシー・セラピューティクス・インコーポレイテッド	腸内好気性化治療
EP4452236A2 (en)	2021-12-23	2024-10-30	Medichem, S.A.	Solid pharmaceutical formulations of varenicline

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4519801A (en)	1982-07-12	1985-05-28	Alza Corporation	Osmotic device with wall comprising cellulose ether and permeability enhancer
GB8613688D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition
GB8616669D0 (en) *	1986-07-09	1986-08-13	Merk Sharpe & Dohme Ltd	Pharmaceutical compositions
JPH0816066B2 (ja) *	1986-07-18	1996-02-21	エーザイ株式会社	持続性薬効製剤
US4943435A (en) *	1987-10-05	1990-07-24	Pharmetrix Corporation	Prolonged activity nicotine patch
US5612059A (en) *	1988-08-30	1997-03-18	Pfizer Inc.	Use of asymmetric membranes in delivery devices
SE8803822D0 (sv)	1988-10-26	1988-10-26		Novel dosage form
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
US5030452A (en) *	1989-01-12	1991-07-09	Pfizer Inc.	Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
US4983401A (en) *	1989-05-22	1991-01-08	Kinaform Technology, Inc.	Sustained release pharmaceutical preparations having pH controlled membrane coatings
JP3084729B2 (ja) *	1990-06-15	2000-09-04	横河電機株式会社	デジタルオシロスコープ
ATE216577T1 (de)	1992-01-29	2002-05-15	Takeda Chemical Industries Ltd	Schnellösliche tablette und ihre herstellung
US5698224A (en)	1994-06-27	1997-12-16	Alza Corporation	Tacrine therapy
US5736159A (en)	1995-04-28	1998-04-07	Andrx Pharmaceuticals, Inc.	Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
RU2066196C1 (ru) *	1995-06-01	1996-09-10	Андрей Борисович Рейзин	Средство "антиник" для облегчения отвыкания от табакокурения и лечения хронических бронхолегочных заболеваний курильщиков
US5948751A (en) *	1996-06-20	1999-09-07	Novo Nordisk A/S	X14-mannitol
US6605610B1 (en)	1997-12-31	2003-08-12	Pfizer Inc	Aryl fused azapolycyclic compounds
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
US6190696B1 (en) *	1998-06-08	2001-02-20	Pieter J. Groenewoud	Stabilized thyroxine medications
EP1064938A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Pharmaceutical dosage forms for controlled release producing at least a timed pulse
AU1444301A (en) *	1999-10-29	2001-05-14	Merck & Co., Inc.	Osmotic controlled release drug delivery device
US6306436B1 (en) *	2000-04-28	2001-10-23	Teva Pharmaceuticals Usa, Inc.	Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
BR0113626A (pt)	2000-08-30	2003-06-17	Pfizer Prod Inc	Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US20030175349A1 (en)	2001-01-30	2003-09-18	Council Of Scientific And Industrial Research	Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EE200300557A (et) *	2001-05-14	2004-04-15	Pfizer Products Inc.	5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
GEP20053712B (en) *	2001-05-14	2005-12-26	Pfizer Prod Inc	Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
WO2003045437A1 (en)	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (en)	2003-05-20	2004-12-02	Pfizer Products Inc.	Pharmaceutical compositions of varenicline
MX2007004495A (es)	2004-10-15	2007-05-10	Pfizer Prod Inc	Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
CN101420939A (zh)	2006-04-24	2009-04-29	辉瑞产品公司	用于药物递送装置的不对称膜

2002
- 2002-11-04 WO PCT/IB2002/004612 patent/WO2003045437A1/en not_active Ceased
- 2002-11-04 MX MXPA04003807A patent/MXPA04003807A/es active IP Right Grant
- 2002-11-04 DE DE60218885T patent/DE60218885T2/de not_active Expired - Lifetime
- 2002-11-04 NZ NZ532435A patent/NZ532435A/en not_active IP Right Cessation
- 2002-11-04 KR KR1020067024203A patent/KR100892517B1/ko not_active Expired - Fee Related
- 2002-11-04 EP EP02785718A patent/EP1448235B1/en not_active Expired - Lifetime
- 2002-11-04 CA CA002467490A patent/CA2467490C/en not_active Expired - Lifetime
- 2002-11-04 IL IL16185702A patent/IL161857A0/xx not_active IP Right Cessation
- 2002-11-04 CN CNA02823751XA patent/CN1596128A/zh active Pending
- 2002-11-04 PT PT02785718T patent/PT1448235E/pt unknown
- 2002-11-04 SI SI200230522T patent/SI1448235T1/sl unknown
- 2002-11-04 KR KR10-2004-7008120A patent/KR20040063975A/ko not_active Ceased
- 2002-11-04 ES ES02785718T patent/ES2282492T3/es not_active Expired - Lifetime
- 2002-11-04 AU AU2002351008A patent/AU2002351008B2/en not_active Ceased
- 2002-11-04 PL PL370913A patent/PL208080B1/pl not_active IP Right Cessation
- 2002-11-04 AT AT02785718T patent/ATE356625T1/de active
- 2002-11-04 JP JP2003546938A patent/JP2005528330A/ja active Pending
- 2002-11-04 BR BR0214806-4A patent/BR0214806A/pt not_active IP Right Cessation
- 2002-11-04 DK DK02785718T patent/DK1448235T3/da active
- 2002-11-04 CN CNA2006100916032A patent/CN1864663A/zh active Pending
- 2002-11-04 RU RU2004116343/15A patent/RU2272629C2/ru not_active IP Right Cessation
- 2002-11-20 PY PY200200228832A patent/PY0228832A/es unknown
- 2002-11-20 US US10/300,608 patent/US7771748B2/en not_active Expired - Fee Related
- 2002-11-25 TW TW091134198A patent/TWI327471B/zh not_active IP Right Cessation
- 2002-11-26 PE PE2002001135A patent/PE20040121A1/es not_active Application Discontinuation
- 2002-11-28 UY UY27553A patent/UY27553A1/es not_active Application Discontinuation
- 2002-11-28 AR ARP020104591A patent/AR037592A1/es not_active Application Discontinuation
- 2002-11-29 SV SV2002001418A patent/SV2004001418A/es not_active Application Discontinuation
- 2002-11-29 GT GT200200247A patent/GT200200247A/es unknown
- 2002-11-29 MY MYPI20024495A patent/MY130619A/en unknown
- 2002-11-29 PA PA20028559501A patent/PA8559501A1/es unknown
2004
- 2004-04-22 ZA ZA200403068A patent/ZA200403068B/en unknown
- 2004-06-29 NO NO20042739A patent/NO20042739L/no not_active Application Discontinuation
2005
- 2005-11-18 RU RU2005135958/14A patent/RU2314810C2/ru not_active IP Right Cessation
2008
- 2008-10-29 JP JP2008278533A patent/JP2009108064A/ja not_active Ceased

Also Published As

Publication number	Publication date
ATE356625T1 (de)	2007-04-15
UY27553A1 (es)	2003-06-30
MXPA04003807A (es)	2004-07-30
US20030180360A1 (en)	2003-09-25
DE60218885T2 (de)	2008-01-17
US7771748B2 (en)	2010-08-10
CA2467490C (en)	2007-01-09
RU2004116343A (ru)	2005-03-27
KR20040063975A (ko)	2004-07-15
SV2004001418A (es)	2004-05-07
RU2005135958A (ru)	2007-06-10
NO20042739L (no)	2004-07-23
DE60218885D1 (de)	2007-04-26
CN1864663A (zh)	2006-11-22
ZA200403068B (en)	2005-04-22
BR0214806A (pt)	2004-09-14
PY0228832A (es)	2004-06-01
WO2003045437A1 (en)	2003-06-05
EP1448235A1 (en)	2004-08-25
JP2005528330A (ja)	2005-09-22
TW200300684A (en)	2003-06-16
IL161857A0 (en)	2005-11-20
KR20060125925A (ko)	2006-12-06
TWI327471B (en)	2010-07-21
AU2002351008A1 (en)	2003-06-10
PL208080B1 (pl)	2011-03-31
NZ532435A (en)	2005-04-29
PA8559501A1 (es)	2003-06-30
ES2282492T3 (es)	2007-10-16
GT200200247A (es)	2003-06-25
JP2009108064A (ja)	2009-05-21
EP1448235B1 (en)	2007-03-14
PT1448235E (pt)	2007-05-31
RU2314810C2 (ru)	2008-01-20
WO2003045437A8 (en)	2003-08-14
MY130619A (en)	2007-07-31
RU2272629C2 (ru)	2006-03-27
AU2002351008B2 (en)	2007-07-12
PE20040121A1 (es)	2004-03-22
CN1596128A (zh)	2005-03-16
SI1448235T1 (sl)	2007-08-31
DK1448235T3 (da)	2007-07-02
AR037592A1 (es)	2004-11-17
KR100892517B1 (ko)	2009-04-10
CA2467490A1 (en)	2003-06-05

Legal Events

Date	Code	Title	Description
2012-02-29	RECP	Rectifications of patent specification
2013-12-31	LAPS	Decisions on the lapse of the protection rights	Effective date: 20121104

Publication	Publication Date	Title
PL370913A1 (pl)	2005-05-30	Środki farmaceutyczne zawierajace 5,7,14-triazatetracyklo [10.3.1.0(2,11).0(4,9)] heksadeka-2(11) 3,5,7,9-pentaen
EE200300556A (et)	2004-04-15	5,8,14-triasatetratsüklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad
ZA200410015B (en)	2005-09-28	Pharmaceutical salts.
MXPA03006884A (es)	2003-11-13	Formulacion farmaceutica.
MXPA03007641A (es)	2003-12-04	Formulacion farmaceutica.
ZA200400926B (en)	2005-02-04	Diamine derivatives.
NO20040540L (no)	2004-02-05	4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
DE60214428D1 (de)	2006-10-12	1, 4-dihydro-1, 4-diphenylpyridin-derivate
AP2003002907A0 (en)	2003-12-31	Liquid pharmaceutical composition.
EE200300557A (et)	2004-04-15	5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
DK1389213T3 (da)	2006-07-10	3,7-Diazabicyclo[3.3.1]formuleringer som antiarytmiske forbindelser
ZA200402729B (en)	2005-01-13	Pharmaceutical formulation comprising (R) -bicalutamide.
IT1308195B1 (it)	2001-12-10	Utensile per la troncatura di arbusti.
ZA200404807B (en)	2005-08-29	Imidazoquinoline derivatives.
DE60213084D1 (de)	2006-08-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
AU2001237377A1 (en)	2001-08-27	3,9-diazabicyclo(3.3.1)nonane derivatives with analgesic activity
ZA200110500B (en)	2002-04-03	Pharmaceutical composition.
MXPA03007318A (es)	2003-12-04	Composicion farmaceutica.
ZA200110501B (en)	2002-04-03	Pharmaceutical composition.
ZA200402731B (en)	2005-01-13	Pharmaceutical formulation.
Nieminen	2001	Sovetskoe zaklûčenie v 40-50-h godah glazami AI Solženicyna
ES1050042Y (es)	2002-06-16	Botellero perfeccionado.
ZA200110499B (en)	2002-04-03	Pharmaceutical composition.
ES1048360Y (es)	2001-12-01	Recipiente perfeccionado.
ES1050420Y (es)	2002-07-16	Gorro perfeccionado.